-
Feb 22, 2021 10:27 AM IST Ryaltris is indicated for symptomatic treatment of seasonal and perennial allergic rhinitis in adults and children over 12 years of age. The drug relieves symptoms of allergic rhinitis, including stuffy nose, runny nose, nasal itching, sneezing, as well as itchy, red and watery eyes.
-
Feb 16, 2021 01:11 PM IST -
Feb 13, 2021 10:20 PM IST The company had posted a net profit of Rs 190.83 crore for the corresponding period of the previous fiscal.
-
Dec 31, 2020 02:15 PM IST The pharmaceutical sector is expecting sales to normalise by the second half of 2021, with the availability of COVID-19 vaccine and coronavirus receding.
-
Nov 09, 2020 01:15 PM IST The company said the worst is behind in terms of US business and expects an uptick in sales from Q3FY21 onwards.
-
Aug 17, 2020 10:55 AM IST -
Aug 17, 2020 10:44 AM IST -
Aug 06, 2020 02:50 PM IST The higher strength will improve compliance for patients by effectively reducing the number of tablets required per day, Glenmark said in a statement.
-
Jul 21, 2020 10:30 AM IST On July 13, Glenmark Pharmaceuticals cut the price of its antiviral drug Favipiravir, under the brand name FabiFlu, by 27 percent to Rs 75 per tablet.
-
Jun 29, 2020 11:11 AM IST -
Jun 29, 2020 10:15 AM IST -
Jun 26, 2020 11:00 AM IST The acquisition was announced in March and was subject to certain closing conditions, which have now been fulfilled, the FMCG firm said in a filing to BSE.
-
Jun 20, 2020 02:09 PM IST FabiFlu is the first oral Favipiravir-approved medication for the treatment of COVID-19, the company said in a statement.
-
May 27, 2020 10:59 AM IST Glenmark Pharmaceuticals Inc, USA has been granted final approval by the US Food and Drug Administration (USFDA) for Chlorzoxazone tablets USP, in strength of 375 mg and 750 mg, the drug maker said in a statement.
-
May 12, 2020 08:45 AM IST The Mumbai-based company had received approval from Drug Controller General of India (DCGI) last month to conduct clinical trials of Favipiravir antiviral tablets for the treatment of COVID-19 patients.
-
May 11, 2020 12:32 PM IST Glenmark Pharmaceuticals on Monday said it has launched a triple therapy inhaler in the country for patients with chronic obstructive pulmonary disease (COPD).
-
Apr 30, 2020 10:15 AM IST Having internally developed the active pharmaceutical ingredients (API) and the formulations for the product, the company filed the product for clinical trials with the DCGI and has received approval for conducting the trial on mild to moderate patients, Glenmark Pharmaceuticals said in a statement.
-
Mar 23, 2020 05:10 PM IST The transaction is subject to fulfilment of certain conditions and both the companies are looking to seal the deal in the next few months.
-
Jan 29, 2020 09:22 AM IST A stronger domestic market foundation helps as a buffer from fluctuating US sales.
-
Nov 11, 2019 12:50 PM IST The approval granted to Glenmark Pharmaceuticals Inc by the US Food and Drug Administration is for Adapalene and Benzoyl Peroxide Gel, 0.1 per cent/2.5 per cent, which is the the generic version of Epiduo gel, 0.1 per cent/2.5 per cent of of Galderma Laboratories LP, the company said in a statement.
-
Oct 14, 2019 04:07 PM IST Net Sales are expected to increase by 2.4 percent Y-o-Y (up 13.8 percent Q-o-Q) to Rs. 2,642.7 crore, according to Emkay.
-
Oct 09, 2019 12:33 PM IST The tentative nod granted by US Food & Drug Administration (USFDA) to Glenmark Pharmaceuticals Inc, USA (Glenmark) is for multiple strengths of dimethyl fumarate delayed-release capsules of 120 mg and 240 mg.
-
Oct 06, 2019 12:16 PM IST The warning letter comes at a time when the company has been struggling with high debt and lack of meaningful approvals for products that can shore-up declining US sales
-
Oct 05, 2019 03:54 PM IST The company believes that the existing manufacturing and the sale of products from this facility will not be impacted, it added.
-
Aug 20, 2019 03:40 PM IST HDFC Securities is bullish on Glenmark has recommended buy rating on the stock with a target price of Rs 500 in its research report dated August 16, 2019.